Concord Drugs Ltd (CONCORD) Announcements - Latest Exchange Filings with AI Summaries
Latest corporate announcements filed by Concord Drugs Ltd on NSE and BSE, with an AI summary of each filing.
Annual general meeting -Scrutinizer''s Report
Annual General Meeting · 01 Oct 2026, 7:06 pm
Summary Proceedings of AGM
Annual General Meeting · 01 Oct 2026, 2:17 am
Letter to members as per regulation 36(1)(b)
Others (Uncategorized) · 08 Sept 2026, 1:03 am
Concord Drugs Dispatches FY26 Annual Report Weblink and Sets AGM Date Concord Drugs Limited informed exchanges on 7th Sep'26 that it is dispatching letters under Regulation 36(1)(b) of SEBI LODR to shareholders without registered email addresses, providing web access to the FY26 Annual Report. The company also announced that its 31st Annual General Meeting is scheduled for 30th Sep'26 at 09:30 AM IST via Video Conferencing/Other Audio Visual Means. Shareholders are urged to update their email records with their respective Depository Participants to receive future electronic corporate communications.
Record date for Annual general meeting
Others · 08 Sept 2026, 12:58 am
31st Annual Report of the Company
Others (Uncategorized) · 08 Sept 2026, 12:51 am
AGM to be held on 30.09.2026 at 09:00 AM
Annual General Meeting · 08 Sept 2026, 12:45 am
Company has approved the notice and proposed to hold 31st AGM on 30.09.2026
Others (Uncategorized) · 08 Sept 2026, 12:42 am
Board of Directors have approved stand alone and consolidated Un-audited financial results for 30th June 2026
Financial Result · 10 Aug 2026, 11:07 pm
Concord Drugs Q1FY27: Strong YoY Profit Growth Amid Revenue Increase Concord Drugs reported strong standalone results for Q1FY27 (quarter ended 30-Jun'26). Revenue from operations grew 56.1% YoY to Rs 2,088.86 lakhs, while net profit surged to Rs 111.23 lakhs from Rs 11.14 lakhs in Q1FY26. On a QoQ basis, revenue declined 41.2% while PAT more than doubled from Rs 51.68 lakhs. The consolidated net profit for the quarter stood at Rs 111.40 lakhs. Basic EPS improved to Rs 0.84 from Rs 0.11 YoY despite a higher equity base.
Outcome of Board meeting
Outcome · 10 Aug 2026, 11:01 pm
Concord Drugs Ltd - Financial Result for the Quarter ended 30th Jun'26 (Consolidated, INR Lakh) ■ Revenue: 2,095 (+53.9% YoY | -44.7% QoQ) ■ EBITDA: 229 (+125.4% YoY | +53.1% QoQ) ■ EBITDA Margin (%): 10.9 (+347 bps YoY | +699 bps QoQ) ■ PAT: 111 (+846.5% YoY | +111.0% QoQ) ■ EPS (INR): 0.85 (+608.3% YoY | +80.9% QoQ)
Concord Drugs Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/08/2026 ,inter alia, to consider and approve Quarterly Results
Intimation · 10 Aug 2026, 5:30 am
Concord Drugs Schedules Board Meeting for Q1FY27 Results Concord Drugs Limited's Board of Directors will meet on 10th Aug'26 to consider and approve the un-audited standalone and consolidated financial results for the quarter ended 30th Jun'26. In compliance with insider trading regulations, the trading window for designated persons has been closed and will reopen 48 hours after the financial results are declared.
Financial Results for Year ending 31st March, 2026
Financial Result · 30 May 2026, 4:41 am
Concord Drugs Ltd - Financial Result for the Quarter ended 31st Mar'26 (Consolidated, INR Lakh) ■ Revenue: 3,790 (+264.5% YoY | +123.1% QoQ) ■ EBITDA: 150 (+42.9% YoY | +58.7% QoQ) ■ EBITDA Margin (%): 3.9 (-612 bps YoY | -160 bps QoQ) ■ PAT: 52.8 (+1253.8% YoY | +143.4% QoQ) ■ EPS (INR): 0.47 (+1075.0% YoY | +193.7% QoQ)
Company has approved financial results for Quarter and year ending 31st March,2026
Outcome · 27 May 2026, 10:02 pm
Concord Drugs Reports Strong FY26 Results with Significant Profit Growth Concord Drugs reported strong consolidated FY26 results with revenue up 74.0% YoY to ₹7,877.13 lakhs. Profit after tax surged 213.8% YoY to ₹105.50 lakhs from ₹33.62 lakhs in FY25, while EPS increased to ₹0.95 from ₹0.34. For Q4FY26, consolidated PAT was ₹52.80 lakhs on revenue of ₹3,789.89 lakhs. The auditor's report highlighted an "Emphasis of Matter" regarding long-outstanding trade receivables of ₹4.14 crores (over 2 years old) for which no provision has been made, which is a key monitorable.
Company in its Board Meeting has approved financial results for period ended 31st March,2026
Financial Result · 27 May 2026, 10:00 pm
Concord Drugs FY26 Results: Profit Surges on Strong Revenue Growth Concord Drugs reported strong FY26 consolidated results, with net profit rising 214% YoY to ₹105.50 lakhs from ₹33.62 lakhs. This was driven by a 74% YoY increase in revenue from operations to ₹7,873.68 lakhs. For Q4 FY26, net profit grew to ₹52.80 lakhs compared to ₹3.90 lakhs YoY, on revenue of ₹3,788.80 lakhs. The board approved the audited financials on 27 May'26. Auditors highlighted long-outstanding trade receivables of ₹4.14 crores with no provision made, though their opinion was unmodified.
Company in its Board Meeting has approved financial results for period ended 31st March,2026
Financial Result · 27 May 2026, 9:59 pm
Concord Drugs Ltd - Financial Result for the Quarter ended 31st Mar'26 (Consolidated, INR Lakh) ■ Revenue: 3,789 (+264.6% YoY | +123.3% QoQ) ■ EBITDA: 149 (+42.6% YoY | +61.2% QoQ) ■ EBITDA Margin (%): 3.9 (-611 bps YoY | -151 bps QoQ) ■ PAT: 52.8 (+1253.8% YoY | +143.4% QoQ) ■ EPS (INR): 0.47 (+1075.0% YoY | +193.7% QoQ)
Concord Drugs Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 27/05/2026 ,inter alia, to consider and approve Financial Results for year ending 31.03.2026
Intimation · 27 May 2026, 5:30 am
Concord Drugs to Announce Q4 & FY26 Results on May 27th Concord Drugs Limited's Board of Directors will meet on 27th May'26 to consider and approve the audited standalone and consolidated financial results for the quarter and year ended 31st Mar'26. In line with insider trading regulations, the trading window for designated persons has been closed and will reopen 48 hours after the financial results are declared.
<b>Format of Initial Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=''1px''><tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> <td><b>Details</b></td> ....
Others (Uncategorized) · 06 May 2026, 11:40 pm
Concord Drugs Confirms It Is Not a "Large Corporate" Under SEBI Norms Concord Drugs Limited informed exchanges on 10 Apr'26 that it does not meet the SEBI criteria to be classified as a “Large Corporate (LC)” as of 31 Mar'26. Consequently, the company is not subject to the mandatory fund-raising requirements through debt securities applicable to LCs. The filing confirms the company had outstanding borrowings of ₹0.00 Cr and no credit rating. This exempts Concord Drugs from the framework's annual disclosure and potential penalties for non-compliance.
<b>Format of the Annual Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=''1px''> <tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> ....
Others (Uncategorized) · 10 Apr 2026, 11:40 pm
Concord Drugs Confirms Non-Applicability of Large Corporate Framework for FY26 Concord Drugs Limited confirmed to the exchange on 10-Apr'26 that it does not qualify as a "Large Corporate" under SEBI regulations as of 31-Mar'26. Consequently, the company is not required to meet the mandatory fund-raising obligations through the issuance of debt securities for the financial year 2025-26. This exemption relieves the company from the specific borrowing framework applicable to larger entities.
<b>Format of Initial Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=''1px''><tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> <td><b>Details</b></td> ....
Others (Uncategorized) · 10 Apr 2026, 11:35 pm
Concord Drugs Not Classified as a Large Corporate for Debt Issuance Concord Drugs Limited informed exchanges on 10 Apr'26 that it does not meet the criteria to be classified as a “Large Corporate” (LC) as of 31 Mar'26, per SEBI's framework. Consequently, the mandatory fund-raising requirements through debt securities and associated annual disclosure obligations are not applicable to the company. This clarifies that Concord Drugs is exempt from the SEBI circulars governing debt issuance by large entities.
General Update
Others (Uncategorized) · 16 Feb 2026, 8:40 pm
Concord Drugs Issues Corrigendum on New Labour Codes Impact Concord Drugs filed a corrigendum on 16 Feb'26 to its Q3 results, correcting an omission from its 14 Feb'26 disclosure. The update clarifies the company's stance on India's new Labour Codes, effective from 21 Nov'25. While Concord has estimated and accounted for potential incremental employee liabilities arising from these codes, it has determined the financial impact to be non-material. The company is awaiting finalization of central and state rules for the new framework. All other previously disclosed financial information remains unchanged.
Un-Audited Stand alone and Consolidated Results for Quarter Ended 31st Dec,2025.
Financial Result · 14 Feb 2026, 10:16 pm
Concord Drugs Q3 FY26 Results: Revenue Jumps YoY, Profitability Contracts Concord Drugs reported consolidated results for the quarter ending 31-Dec'25. Revenue from operations increased 57.1% YoY to ₹1,696.63 lakh, driven by strong sales. However, profit after tax declined 4.3% YoY to ₹21.69 lakh from ₹22.67 lakh in the prior year's quarter. The profit contraction was primarily due to a significant rise in the cost of materials consumed. On a QoQ basis, revenue grew 65.1%, and net profit increased 12.7%. The company also raised ₹13.36 crore via preferential issues during the quarter.
Board of Directors approved financial results for 31 st December,2025
Outcome · 14 Feb 2026, 10:07 pm
CONCORD DRUGS LIMITED - Financial Result for the Quarter ended 31st Dec'25 (Consolidated, INR Lakhs) ■ Revenue: 1699 (+57.3% YoY | +65.3% QoQ) ■ EBITDA: 94.3 (-32.4% YoY | -14.2% QoQ) ■ EBITDA Margin (%): 5.5 (-736 bps YoY | -514 bps QoQ) ■ PAT: 21.7 (-4.3% YoY | +12.7% QoQ) ■ EPS (INR): 0.16 (-30.4% YoY | -15.8% QoQ)
Reconstitution of Committees
Others (Uncategorized) · 14 Feb 2026, 10:04 pm
Concord Drugs Reconstitutes Key Board Committees Concord Drugs Limited announced the reconstitution of its Board Committees, effective 14 Feb '26. Non-Executive Independent Director Kasu Sumeela has been appointed Chairperson of the Audit Committee, Nomination & Remuneration Committee, and the Stakeholders' Relationship Committee. S. Nagavenkata Hareesh and Satyam Reddy Gopidi, both Non-Executive Independent Directors, will serve as members on the Audit and Nomination & Remuneration Committees. The changes are to ensure compliance with statutory requirements.
Announcement under Regulation 30 of LODR
Change in Management · 14 Feb 2026, 10:00 pm
Concord Drugs Reconstitutes Board Committees, Announces Director Cessation Concord Drugs announced Board Committee reconstitutions effective 14-Feb-26. Kasu Sumeela will now chair the Audit, Nomination & Remuneration, and Stakeholders' Relationship Committees. S. Nagavenkata Hareesh and Satyam Reddy Gopidi will serve as members on these committees. Additionally, Independent Director Ramchandra Reddy Kommula has ceased to be a Director from 14-Feb-26 upon completion of his term. The company confirmed there are no other material reasons for his departure.
Concord Drugs Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/02/2026 ,inter alia, to consider and approve Un-Audited financials Results ....
Intimation · 14 Feb 2026, 5:30 am
Concord Drugs to Announce Q3 FY26 Results on 14th Feb'26 Concord Drugs Limited's Board of Directors will meet on 14th Feb'26 to consider and approve the un-audited standalone and consolidated financial results for the quarter ended 31st Dec'25. The trading window for designated persons has been closed and will reopen 48 hours after the results are declared.
Company has received purchase orders from various entities for supply of it''s products.
Others (Uncategorized) · 30 Dec 2025, 5:01 pm
Concord Drugs Secures ₹14.71 Crore in New Purchase Orders Concord Drugs announced on 29 Dec'25 that it has received significant domestic purchase orders aggregating to approximately ₹14.71 crore. The orders are for the supply of various pharmaceutical products to entities including Tamil Nadu Medical Services Corporation and Telangana State Medical Services & Infrastructure Development Corporation. The contracts are to be executed within the next 45 to 60 days. The company confirmed these are not related-party transactions and are expected to positively impact business operations.